if you are interested in it , Get free samples :sales@edabearings.com

With the support of the Ministry of science and technology, the National Health Commission, the State Food and Drug Administration and other departments, the registration and approval of clinical trials of the antiviral drug remdesivir has been completed, and the first group of cases has been put in place. The first group of severe pneumonia patients infected with the new coronavirus will receive medication on February 6.
This is the information learned by Xinhua News Agency reporter on the afternoon of February 5 at the kick-off meeting of the project of "Research on the treatment of 2019 new coronavirus infection by radcivir" held by the Ministry of science and technology in Wuhan Jinyintan hospital.
Professor Cao Bin, who is in charge of clinical trial project of radcivir and vice president of China Japan Friendship Hospital, introduced that radcivir is a drug under research of Gilead company in the United States. In the early stage of cell and animal experiments, it has shown good antiviral activity against SARS coronavirus and mers coronavirus. Recently, clinical trials of radcivir against Ebola coronavirus infection have been carried out abroad, Chinese scholars report that radcivir also has good activity for 2019 new coronavirus at the cellular level, but it still needs rigorous clinical trial evaluation before being used in human body. At present, there is a lack of effective antiviral drugs for patients with new coronavirus infection, and we expect the clinical manifestations of ridcivir.

---

PREVIOUS:Diagnosis of 30 hour newborn born in Wuhan        NEXT:The new Apple TV 4K may be released with A12 chip